Aktiesnakken — November 2019
-
ISS fortsætter med at falde, skal blive spændende at se hvor langt den kommer ned
-
Bryan Garnier hæver target på Genmab til 1550 fra 1500
-
Nervepirrende regnskabssæson, ligger tungt i Novo og Vestas, så jeg ånder lettet op. Hvad siger i andre ?
-
Bloomberg Markets @markets
#5things -Tariff roll back -Impeachment latest -BOE decision -Markets rise -Coming up... https://bloom.bg/2rmjZAp -
Danske Bank Research @Danske_Research
-
Bloomberg Markets @markets
U.K. Chancellor Sajid Javid announces new fiscal rules that will allow the government to borrow for increased investment https://bloom.bg/2reEfDR -
Bloomberg Markets @markets
The reflation trade doesn't need inflation to make a comeback https://bloom.bg/36GalJ1 -
Helge J. Pedersen @helgejpedersen
Sorry to say, but this forecast for Denmark is already outdated given today's GDP revisions for 2016-2018. Will be much lower than 2% (close to 1%) due to an upgrade of GDP growth for 2018 by no less than 0.9%-points from 1.5 to 2.4%! https://twitter.com/EU_Commission/status/1192386892211339266 … -
Bloomberg Economics @economics
Israel is pushing to upgrade major trade agreements to help boost the country’s growing technology exports https://bloom.bg/2WQ45df -
EU-kommisjonen tror på lavere vekst i eurosonen
2 timer siden · Infront TDN Direkt
EU-kommisjonen nedjusterer BNP-vekstanslaget for eurosonen i 2019 til 1,1 prosent og til 1,2 prosent i 2020.
Det opplyser kommisjonen torsdag.
De nye anslagene er nedjustert fra anslaget på 1,2 prosent for 2019 og 1,4 prosent for 2020 fra 10. juli. -
ov. 7, 2019 7:34 AM ET|About: Teva Pharmaceutical In... (TEVA)|By: Douglas W. House, SA News Editor
Teva Pharmaceutical Industries (NYSE:TEVA) Q3 results:
Revenues: $4,264M (-5.9%).
Key product sales: Copaxone: $397M (-33.9%); Generics: $2,224B (-1.8%).
Net loss: ($314M) (-15.0%); non-GAAP net income: $637M (-8.2%); loss/share: ($0.29) (-7.4%); non-GAAP EPS: $0.58 (-14.7%).
Cash flow ops: $325M (-22.8%).
2019 guidance: Revenues: $17.2B - 17.4B from $17.0B - 17.4B;
-
operating income: $4.0B - 4.2B from $3.8B - 4.2B; EBITDA: $4.5B - 4.8B from $4.4B - 4.8B; EPS: $2.30 - 2.50 from $2.20 - 2.50; free cash flow: $1.7B - 2.0B from $1.6B - 2.0B.
Eli Kalif appointed EVP and Chief Financial Officer effective December 22. He joins the firm from Flex Ltd where he was SVP Finance Global Operations, Components & Services.
-
Jeg er også lidt blandet pt. Jeg ligger tungt i Velo og Chemometec, og efter nogle ekstremt gode dage står jeg lidt i et vadested.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind